Success Metrics

Completion Rate
0%(0/2)
Active Trials
7(64%)
Terminated
2(18%)

Phase Distribution

Ph phase_3
1
9%
Ph early_phase_1
1
9%
Ph phase_1
3
27%
Ph phase_2
5
45%

Phase Distribution

4

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Terminated(2)
Other(1)

Detailed Status

Recruiting6
Terminated2
Active, not recruiting1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 13 (30.0%)
Phase 25 (50.0%)
Phase 31 (10.0%)

Trials by Status

active_not_recruiting19%
not_yet_recruiting19%
recruiting655%
terminated218%
unknown19%

Recent Activity

7 active trials
Showing 5 of 11
recruitingphase_2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069
not_yet_recruitingphase_2

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

NCT07206849
recruitingphase_1

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

NCT06965114
recruitingphase_1

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

NCT07441707
active_not_recruitingphase_3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05828069Phase 2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
NCT07206849Phase 2

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

Not Yet Recruiting
NCT06965114Phase 1

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Recruiting
NCT07441707Phase 1

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

Recruiting
NCT05566795Phase 3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Active Not Recruiting
NCT05465174Phase 2

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
NCT04985604Phase 2

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Terminated
NCT07121829Phase 1

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Terminated
NCT06381570Early Phase 1

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting
NCT04775485Phase 2

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Recruiting
NCT05760586

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11